Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
OGI vs TLRY: A Close Look at Two Canadian Cannabis Names Trading Near Lows

OGI vs TLRY: A Close Look at Two Canadian Cannabis Names Trading Near Lows

Key Takeaways

  • OGI is a Canadian pure-play cannabis producer that has used acquisitions to build the country's top market-share position and expand into Europe, while TLRY has diversified into beverages, wellness, and pharmaceutical distribution.
  • Both stocks are trading near 52-week lows, but TLRY carries a substantially larger revenue base and a net cash position, whereas OGI remains below $1 per share with a reduced cash balance.
  • Tickeron AI Verdict: TLRY — based on diversification, balance-sheet stability, and broader revenue consistency, the AI framework would currently favor Tilray Brands over Organigram.
  • OGI has delivered stronger recent revenue growth and a high-profile acquisition catalyst, but carries more concentrated, single-sector risk.
  • For more context, explore OGI Major News and OGI Today's Price Move, as well as TLRY Major News and TLRY Today's Price Move.
  • To see which tickers AI trading systems are currently prioritizing, visit the Trending AI Robots page.

Why These Two Stocks Matter Right Now

Investors tracking the volatile cannabis sector frequently weigh OGI and TLRY against one another, given that both are Nasdaq-listed names with Canadian roots and international ambitions. This comparison is particularly relevant for traders and long-term investors evaluating how two companies with very different strategic paths — one a focused cannabis operator, the other a diversified consumer packaged goods and lifestyle business — are positioned in the current market environment. By examining relative performance, growth drivers, balance-sheet strength, and recent momentum, readers can better understand the trade-offs between these two names. I also checked sector peers using Tickeron’s AI Screener to confirm the relative positioning.

Organigram’s Focus and Recent Moves

OGI is Organigram Global Inc., a licensed Canadian cannabis producer headquartered in Toronto. The company has grown into Canada's number-one cannabis operator by market share, with leadership across categories such as vapes, milled flower, and concentrates. In recent weeks, Organigram has been reshaping itself into a global platform: it completed the acquisition of Germany-based Sanity Group earlier this year and, more recently, agreed to acquire Aurora Cannabis in a transaction backed by strategic investor British American Tobacco. These moves have extended Organigram's reach into European medical cannabis markets.

Financially, Organigram reported record quarterly results in its most recent fiscal quarter, with net revenue rising roughly 49% year over year and adjusted EBITDA more than doubling, driven largely by Sanity's contribution. However, the company's cash position declined sharply following these acquisitions, and its shares have traded near 52-week lows and below the $1 threshold, prompting a Nasdaq listing notification with no immediate effect on trading. Sentiment remains mixed: strong strategic momentum is offset by balance-sheet constraints and continued share-price pressure. When I reviewed the latest signals, Tickeron’s AI Daily Buy/Sell Signals highlighted the ongoing volatility.

Tilray’s Broader Approach and Financial Position

TLRY is Tilray Brands, Inc., a global lifestyle and consumer packaged goods company operating at the intersection of cannabis, beverages, wellness, and pharmaceutical distribution across more than 20 countries. Unlike a pure-play cannabis firm, Tilray generates a large share of its revenue from craft beer and spirits, notably following its acquisition of the BrewDog brand, as well as from its European pharmaceutical distribution network. This diversification has made beverages its largest revenue segment in recent quarters.

In its most recent reported quarter, Tilray posted record revenue with double-digit year-over-year growth, led by an 82% jump in beverage sales and continued strength in international cannabis. Cannabis revenue itself declined year over year as management prioritized margins over volume in Canada's competitive adult-use market. Tilray has also improved its financial position, ending recent periods with a net cash position after reducing debt meaningfully. Still, the company continues to report net losses, and its shares have fallen sharply over the past year, trading near multi-year lows despite the improving fundamentals.

Key Differences in Strategy and Risk

The core contrast between these two companies is concentration versus diversification. OGI is a focused cannabis operator whose growth is tied to market-share gains in Canada and expansion into European medical markets through M&A. That focus has produced some of the strongest top-line growth in the sector, but it also leaves the company exposed to cannabis-specific pricing pressure, regulatory risk, and integration costs.

TLRY, by contrast, spreads its revenue across cannabis, alcoholic beverages, wellness products, and pharmaceutical distribution. This reduces reliance on any single catalyst, such as U.S. federal cannabis reform, but also dilutes exposure to a pure cannabis recovery. On the balance sheet, Tilray's net cash position and larger scale offer more financial flexibility, whereas Organigram's thinner cash reserves and sub-$1 share price introduce greater near-term risk. In terms of momentum, both stocks remain in downtrends, but Tilray's broader revenue base provides comparatively steadier positioning.

AI Framework Assessment

Weighing trend consistency, financial stability, and relative market positioning, a Tickeron-style AI framework would likely favor TLRY over OGI at present. Tilray's diversified revenue streams, net cash balance sheet, and larger scale offer a comparatively more stable foundation, even as it remains unprofitable. Organigram presents a more compelling near-term growth and M&A catalyst, but its concentrated business model, reduced liquidity, and below-$1 share price introduce materially higher risk. This assessment reflects observable, probabilistic factors rather than a definitive prediction, and the relative ranking could shift as either company's fundamentals or market conditions evolve. I cross-checked the latest patterns with Tickeron’s AI Pattern Search Engine to validate the trends.

Exploring AI-Driven Trading Approaches

For traders who prefer a data-driven approach to decisions like this one, Tickeron’s Trending AI Robots page offers a curated view of the platform's automated trading systems. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only a select group — those best suited to current market conditions — earn a place in this trending section. These bots vary widely in trading style, strategy, timeframe, historical performance, and the specific tickers they follow, allowing investors to match a system to their own objectives. The page is designed to help users identify which strategies are performing most effectively right now, making it a practical starting point for anyone exploring AI-driven market analysis.

My Experience with Tickeron’s AI Trend Prediction Engine

I often turn to Tickeron’s AI Trend Prediction Engine when comparing names like these two. It helps me quickly gauge momentum across multiple timeframes and see how recent news flows might influence price action. The tool has been useful for spotting divergences between fundamentals and technical signals without having to build custom models from scratch. In this case it reinforced the edge in stability for the more diversified name while flagging the higher-risk profile of the pure-play grower.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TLRY, OGI

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for TLRY turns negative, indicating new downward trend

TLRY saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 72 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 40 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -7%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 411%, while BFRI experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 8 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
3595
Web
https://www.tilray.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.